| 摘要 |
The present invention relates to a soluble lymphotoxin (solLT) and methods of using the solLT as a biomarker in the treatment of autoimmune disease. More particularly, the present invention relates to soluble lymphotoxin alpha-beta (solLTα&bgr;) and methods of using this solLTα&bgr; as a biomarker in the treatment of rheumatoid arthritis (RA).
|
